Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Utah Medical Products

This article was originally published in The Gray Sheet

Executive Summary

Will begin shipments of its Toco Bubble in approximately one month. The dynamometer device is designed to measure uterine contraction during labor and delivery. The firm began taking orders for the device immediately after receiving FDA 510(k) clearance for the product on June 4. The company says the Toco Bubble, which is several inches in diameter and adheres directly to the abdomen, is intended to replace belt devices that currently are used to measure uterine contractions. The device is disposable and sells for $5 to hospitals. The firm sells connector tubing and a reusable adaptor designed to connect the device to a monitor separately. On June 15, Utah announced that it no longer is under investigation by the Securities and Exchange Commission. Records subpoenaed in 1992 by the Department of Justice, Utah district, recently were returned to the company. Although it never was informed of the reasons for the investigation, the company says it may have been in connection with the indictment of former president and CEO William Dean Wallace on charges that included insider trading and falsification of firm records. Wallace was acquitted in December 1992 ("The Gray Sheet" Jan. 4, In Brief).

You may also be interested in...



Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel